相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2023)
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2023)
How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
Yu Kataoka et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2022)
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment
David Kallend et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2022)
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
Wolfgang Koenig et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser et al.
CARDIOVASCULAR RESEARCH (2021)
Givosiran: A Review in Acute Hepatic Porphyria
Yahiya Y. Syed
DRUGS (2021)
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy
Hiroyuki Omori et al.
JACC-CARDIOVASCULAR IMAGING (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Kausik K. Ray et al.
JAMA CARDIOLOGY (2019)
PCSK9 inhibitors: clinical evidence and implementation
Marc S. Sabatine
NATURE REVIEWS CARDIOLOGY (2019)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins Prespecified Secondary End Points in ORION 1
Kausik K. Ray et al.
CIRCULATION (2018)
THE EFFECT OF PCSK9 INHIBITION ON BIOMARKERS OF ATHEROSCLEROTIC PLAQUE DESTABILIZATION RELEASE IN HYPERTENSIVE PATIENT WITH DYSLIPIDEMIA
B. Okopien et al.
JOURNAL OF HYPERTENSION (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
INFLUENCE OF PCSK9 INHIBITION ON THE STABILIZATION OF ATHEROSCLEROTIC PLAQUE DETERMINED BY BIOCHEMICAL METHODS AND MAGNETIC RESONANCE IMAGING
M. Basiak et al.
ATHEROSCLEROSIS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe
Kamlesh Khunti et al.
JAMA NETWORK OPEN (2018)
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program
Robert M. Stoekenbroek et al.
FUTURE CARDIOLOGY (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
John J. P. Kastelein et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Targeting Therapeutic Oligonucleotides
Arthur A. Levin
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs
Anastasia Khvorova
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
Zhihan Tang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
S. A. Mousavi et al.
JOURNAL OF INTERNAL MEDICINE (2009)
分享论文
